- Factors associated with Oncology Nurses' Adherence to Chemotherapy-Induced Neutropenia Guidelines based on Pender's Health Promotion Model
-
Kim GJ, Choi JY
- KMID: 2455721
- Korean J Adult Nurs.
- 2019 Aug;31(4):389-402.
- doi: 10.7475/kjan.2019.31.4.389
PURPOSE: This study was conducted to identify factors associated with oncology nurses' adherence to Chemotherapy-Induced Neutropenia (CIN) guidelines based on Pender's Health Promotion Model (HPM). METHODS: For this cross-sectional descriptive study,... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
-
Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, Kim IJ, Kim SI, Park S, Park HS, Kim GM
- KMID: 2176324
- J Breast Cancer.
- 2016 Mar;19(1):76-82.
- doi: 10.4048/jbc.2016.19.1.76
PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using... -
- CITED
-
- Close
- SHARE
-
- Close
- Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
-
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS
- KMID: 2069930
- J Korean Med Sci.
- 2014 Nov;29(11):1493-1500.
- doi: 10.3346/jkms.2014.29.11.1493
Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia... -
- CITED
-
- Close
- SHARE
-
- Close
